A pharmacological analysis of the cholinergic regulation of urokinase-type plasminogen activator secretion in the human colon cancer cell line, HT-29

European Journal of Pharmacology

Volumn 646, Issue 1-3, 2010, Pages 22-30

  Novotny, Ann ^a   Edsparr, Karin ^a   Nylund, Gunnar ^b   Khorram Manesh, Amir ^a   Albertsson, Per ^a   Nordgren, Svante ^a   Delbro, Dick S ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Section of Rheumatology   (Sweden)

^c KARLSTAD UNIVERSITY   (Sweden)

Author keywords

Acetylcholine; Choline acetyltransferase; HT 29 colon cancer cell line; Nicotine; Urokinase type plasminogen activator; Urokinase type plasminogen activator receptor

Indexed keywords

ACETYLCHOLINE; ALPHA BUNGAROTOXIN; BUNGAROTOXIN RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CELL STIMULATION; CELL STRAIN HT29; CHOLINERGIC STIMULATION; COLON CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; WESTERN BLOTTING;

ACETYLCHOLINE; CELL PROLIFERATION; CHOLINERGIC AGENTS; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; NICOTINE; RECEPTORS, NICOTINIC; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77956993580     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.08.004     Document Type: Article

References (57)

1. Adachi Y., Li R., Yamamoto H., Min Y., Piao W., Wang Y., Imsumran A., Li H., Arimura Y., Lee C.-T., Imai K., Carbone D.P., Shinomura Y. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin. Carcinogenesis 2009, 30:1305-1313.
2. Aguirre Ghiso J.A., Alonso D.F., Farías E.F., Gomez D.E., de Kier Joffè E.B. Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur. J. Biochem. 1999, 263:295-304.
3. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993, 15:105-111.
4. Buø L., Bjørnland K., Karlsrud T.S., Kvale D., Kjønniksen I., Fodstad O., Brandtzaeg P., Johansen H.T., Aasen A.O. Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines. Anticancer Res. 1994, 14:2445-2451.
5. Cajot J.F., Sordat B., Bachmann F. Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment. J. Natl Cancer Inst. 1986, 77:1099-1107.
6. Chen D., Patrick J.W. The α-Bungarotoxin-binding nicotinic acetylcholine receptor from rat brain contains only the α7 subunit. J. Biol. Chem. 1997, 272:24024-24029.
7. Corasanti J.G., Celik C., Camiolo S.M., Mittelman A., Evers J.L., Barbasch A., Hobika G.H., Markus G. Plasminogen activator content of human colon tumors and normal mucosae: separation of enzymes and partial purification. J. Natl Cancer Inst. 1980, 65:345-351.
8. Dass K., Ahmad A., Azmi A.S., Sarkar S.H., Sarkar F.H. Evolving role of uPA/uPAR system in human cancers. Cancer Treat. Rev. 2008, 34:122-136.
9. Gach K., Szemraj J., Fichna J., Piestrzeniewicz M., Delbro D.S., Janecka A. The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line. Chem. Biol. Drug Des. 2009, 74:390-396.
10. Gelister J.S., Jass J.R., Mahmoud M., Gaffney P.J., Boulos P.B. Role of urokinase in colorectal neoplasia. Br. J. Surg. 1987, 74:460-463.
11. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
12. Harvey S.R., Lawrence D.D., Madeja J.M., Abbey S.J., Markus G. Secretion of plasminogen activators by human colorectal and gastric tumor explants. Clin. Exp. Metastasis 1988, 6:431-450.
13. Harvey S.R., Sait S.N.J., Xu Y., Bailey J.L., Penetrante R.M., Markus G. Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am. J. Pathol. 1999, 155:1115-1120.
14. Harvey S., Kohga S., Sait S.N.J., Markus G., Hurd T.C., Martinick M., Geradts J., Saxena R., Gibbs J.F. Co-expression of urokinase with haptoglobin in human carcinomas. J. Surg. Res. 2009, 152:189-197.
15. Horiuchi Y., Kimura R., Kato N., Fujii T., Seki M., Endo T., Kato T., Kawashima K. Evolutional study on acetylcholine expression. Life Sci. 2003, 72:1745-1756.
16. Ikeda C., Morita I., Mori A., Fujimoto K., Suzuki T., Kawashima K., Murota S. Phorbol ester stimulates acetylcholine synthesis in cultured endothelial cells isolated from porcine cerebral microvessels. Brain Res. 1994, 655:147-152.
17. Illemann M., Bird N., Majeed A., Lærum O.D., Lund L.R., Danø K., Schnack Nielsen B. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int. J. Cancer 2009, 124:1860-1870.
18. Jones S.L., Quinn D., Ma J., Ward H.A., Pihl E., Nairn R.C. Persistence of organ- and iso-antigens in vitro in a long-term culture cell line of colonic carcinoma. Pathology 1982, 14:405-408.
19. Kanefsky J., Lenburg M., Hai C.M. Cholinergic receptor and cyclic stretch-mediated inflammatory gene expression in intact ASM. Am. J. Respir. Cell Mol. Biol. 2006, 34:417-425.
20. Katono T., Kawato T., Tanabe N., Suzuki N., Yamanaka K., Oka H., Motohashi M., Maeno M. Nicotine treatment induces expression of matrix metalloproteinases in human osteoblastic Saos-2 cells. Acta Biochim. Biophys. Sin. (Shanghai) 2006, 38:874-882.
21. Katono T., Kawato T., Tanabe N., Tanaka H., Suzuki N., Kitami S., Morita T., Motohashi M., Maeno M. Effects of nicotine and lipopolysaccharide on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in human osteoblasts. Arch. Oral Biol. 2009, 54:146-155.
22. Kim T.-D., Song K.-S., Li G., Choi H., Park H.-D., Lim K., Hwang B.-D., Yoon W.-H. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006, 6:211.
23. Klapproth H., Reinheimer T., Metzen J., Münch M., Bittinger F., Kirkpatrick C.J., Höhle K.D., Schemann M., Racké K., Wessler I. Non-neuronal acetylcholine, a signalling molecule synthezised by surface cells of rat and man. Naunyn Schmiedebergs Arch. Pharmacol. 1997, 355:515-523.
24. Laufs S., Schumacher J., Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 2006, 5:1760-1771.
25. Markus G. The relevance of plasminogen activators to neoplastic growth. A review of recent literature. Enzyme 1988, 40:158-172.
26. Markus G., Camiolo S.M., Kohga S., Madeja J.M., Mittelman A. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors. Cancer Res. 1983, 43:5517-5525.
27. Minoo P., Baker K., Baumhoer D., Terracciano L., Lugli A., Zlobec I. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum. Pathol. 2010, 41:70-78.
28. Moore N.H., Costa L.G., Shaffer S.A., Goodlett D.R., Guizzetti M. Shotgun proteomics implicates extracellular matrix proteins and protease systems in neuronal development induced by astrocyte cholinergic stimulation. J. Neurochem. 2009, 108:891-908.
29. Nylund G., Pettersson A., Bengtsson C., Khorram-Manesh A., Nordgren S., Delbro D.S. Functional expression of mu-opioid receptors in the human colon cancer cell line, HT-29, and their localization in human colon. Dig. Dis. Sci. 2008, 53:461-466.
30. Okumura S., Yuki K., Kobayashi R., Okamura S., Ohmori K., Saito H., Ra C., Okayama Y. Hyperexpression of NOD2 in intestinal mast cells of Crohn's disease patients: preferential expression of inflammatory cell-recruiting molecules via NOD2 in mast cells. Clin. Immunol. 2009, 130:175-185.
31. Pettersson A., Nilsson L., Edsparr K., Nylund G., Khorram-Manesh A., Albertsson P., Nordgren S., Delbro D.S. Is acetylcholine an autocrine growth factor in human colon cancer cells?. Virchows Arch. 2008, 452(Suppl 1):S194.
32. Pettersson A., Nilsson L., Nylund G., Khorram-Manesh A., Nordgren S., Delbro D.S. Is acetylcholine an autocrine/paracrine growth factor via the nicotinic α7-receptor subtype in the human colon cancer cell line HT-29?. Eur. J. Pharmacol. 2009, 609:27-33.
33. Pyke C., Kristensen P., Ralfkiaer E., Grøndahl-Hansen J., Eriksen J., Blasi F., Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 1991, 138:1059-1067.
34. Pyke C., Ralfkiaer E., Rønne E., Høyer-Hansen G., Kirkeby L., Danø K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994, 24:131-138.
35. Rodriguez-Fragoso L., Alvarez R., Reyes-Esparza J.A., Garcés M.E. Acetaldehyde increases the activity and gene expression of urokinase type plasminogen activator in a hepatic stellate cell line. Toxicology 1999, 137:1-11.
36. Roychoudhury P.K., Khaparde S.S., Mattiasson B., Kumar A. Synthesis, regulation and production of urokinase using mammalian cell culture: a comprehensive review. Biotechnol. Adv. 2006, 24:514-528.
37. Sastry B.V.R., Sadavongvivad C. Cholinergic systems in non-nervous tissues. Pharmacol. Rev. 1978, 30:65-132.
38. Schuller H.M. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors?. Nat. Rev. Cancer 2009, 9:195-205.
39. Seetoo D.Q., Crowe P.J., Russell P.J., Yang J.L. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J. Surg. Oncol. 2003, 82:184-193.
40. Shah V., Kumar S., Zirvi K.A. Metastasis of human colon tumor cells in vivo: correlation with the overexpression of plasminogen activators and 72kDa gelatinase. In Vivo 1994, 8:321-326.
41. Shah N., Khurana S., Cheng K., Raufmann J.P. Muscarinic receptors and ligands in cancer. Am. J. Physiol. Cell Physiol. 2009, 296:C221-C232.
42. Shin V.Y., Wu W.K., Chu K.-M., Wong H.P., Lam E.K., Tai E.K., Koo M.W., Cho C.-H. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Mol. Cancer Res. 2005, 3:607-615.
43. Skelly M.M., Troy A., Duffy M.J., Mulcahy H.E., Duggan C., Connell T.G., O'Donoghue D.P., Sheahan K. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin. Cancer Res. 1997, 3:1837-1840.
44. Slavíková J., Tucek S. Choline acetyltransferase in the heart of adult rats. Pflügers Arch. 1982, 392:225-229.
45. Song P., Spindel E.R. Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in lung cancer provides a new target for cancer therapy. J. Pharmacol. Sci. 2008, 106:180-185.
46. Song P., Sekhon H.S., Proskocil B., Blusztajn J.K., Mark G.P., Spindel E.R. Synthesis of acetylcholine by lung cancer. Life Sci. 2003, 72:2159-2168.
47. Summers A.E., Whelan C.J., Parsons M.E. Nicotinic acetylcholine receptor subunits and receptor activity in the epithelial cell line HT29. Life Sci. 2003, 72:2091-2094.
48. Suzuki S., Hayashi Y., Wang Y., Nakamura T., Morita Y., Kawasaki K., Ohta K., Aoyama N., Kim S.R., Itoh H., Kuroda Y., Doe W.F. Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut 1998, 43:798-805.
49. Tucek S. The synthesis of acetylcholine in skeletal muscles of the rat. J. Physiol. 1982, 322:53-69.
50. Wang W., Abbruzzese J.L., Evans D.B., Chiao P.J. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 1999, 18:4554-4563.
51. Wang M., Vogel I., Kalthoff H. Correlation between metastatic potential and variants from colorectal tumor cell line HT-29. World J. Gastroenterol. 2003, 9:2627-2631.
52. Wang X., Li X., Li Y. A modified Coomassie Brilliant Blue staining method at nanogram sensitivity compatible with proteomic analysis. Biotechnol. Lett. 2007, 29:1599-1603.
53. Wei P.-L., Chang Y.-J., Ho Y.-S., Lee C.-H., Yang Y.-Y., An J., Lin S.-Y. Tobacco-specific carcinogen enhances colon cancer cell migration through α7-nicotinic acetylcholine receptor. Ann. Surg. 2009, 249:978-985.
54. Westfall T.C., Westfall D.P. Neurotransmission: the autonomic and somatic motor nervous systems. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2005, 137-181. McGraw-Hill, New York. 11th ed. J.S. Lazo, K.L. Parker, L.L. Brunton (Eds.).
55. Xie G., Cheng K., Shant J., Raufman J.P. Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G755-G763.
56. Yang L., Avila H., Wang H., Trevino J., Gallick G.E., Kitadai Y., Sasaki T., Boyd D.D. Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density-implications in tumor progression. Cancer Res. 2006, 66:7957-7967.
57. Zorio E., Gilabert-Estellés J., España F., Ramón L.A., Cosín R., Estellés A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr. Med. Chem. 2008, 15:923-929.